GlassScriptPhysician profile
Brett M Ryabik
NPI 1033499066
$2,216.37
in general payments reported to CMS, 2019-2025
12 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $77.17 · 2021: $218 · 2022: $424 · 2023: $486 · 2024: $375 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $697.74 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $556.64 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $201.95 | 2022-2024 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $186.70 | 2024-2025 | Uzedy |
| Indivior INC. | $162.24 | 2021-2023 | Perseris |
| Janssen Pharmaceuticals, INC | $95.02 | 2019-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $85.41 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $67.60 | 2023-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.29 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $62.43 | 2019-2020 | |
| Bioxcel Therapeutics, INC. | $18.66 | 2024 | Igalmi |
| Janssen Scientific Affairs, LLC | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Ryabik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.